Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 10« First...23456...10...Last »

New acne diagnoses linked to increased MDD risk

In the first year after being told by a doctor that they have acne, patients’ risk for a diagnosis of major depressive disorder spikes by more than 60 percent compared to the general population.

Read More »

St. Jude Children’s Research Hospital to develop $412 million advanced research center to propel discovery and scientific breakthroughse

A new era of scientific advancement is emerging at St. Jude Children’s Research Hospital with the development of a $412-million advanced research center, the institution announced.

Read More »

Data Shows Long-Term Skin Clearance With Tremfya

New data from the VOYAGE 2 club incalculable trial demonstrated high efficacy response rates were achieved with continuous Tremfya (guselkumab) treatment versus withdrawal.

Read More »

Otezla Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers

Celgene Corporation announced that data from the phase III RELIEF clinical trial of Oteza (apremilast) in patients with active Behçet’s Disease showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily versus placebo through week 12.

Read More »

Biosimilar CT-P13 comparable to reference infliximab and adalimumab in highly anticipated real-world study

PANTS study shows that CT-P13 is an efficacious therapy option when investigating personalised approaches to anti-TNF therapy.

Read More »

FDA clears AstraZeneca’s lung cancer immunotherapy

The U.S. FDA granted approval for expanded use of AstraZeneca‘s immunotherapy drug Imfinzi to treat non-small cell lung cancer whose tumors can not be surgically removed.

Read More »

Gilead wins hepatitis C drug patent verdict reversal

A federal judge in Delaware overturned a jury’s verdict requiring Gilead to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co.

Read More »

Agenda 2018 Special Feature: The song remains the same

The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.

Read More »

Agenda 2018: Choose your own adventure

Med Ad News asked its sources what are some of the key industry trends for 2018.

Read More »

Agenda 2018: The AMAZON-IFICATION of health is here

It’s not a new trend. For years, there has been massive speculation on the many ways Amazon could be getting into healthcare. But if you look past the hype, beyond Amazon’s theoretical intentions, and focus more closely on today’s consumer, there is a colossal healthcare trend underway even without Amazon getting in on the game. One can learn a lot from the trend of Amazon’s influence on the business of doing business. So let’s take a closer look …

Read More »

Agenda 2018: PwC Health Research Institute’s top health industry issues of 2018

According to the consultants at PwC, the top health industry issues of 2018 will be …

Read More »

Top 10 Pipelines 2018 Annual Report

Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.

Read More »

Special Feature – Value of Medicines: The value equation

As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.

Read More »

Value of Medicines: PBM waste makes valuable drugs valueless

On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.

Read More »

Medical Advertising Hall of Fame 2018

Robert Leverte Jr. was honored by the Medical Advertising Hall of Fame as its 2018 inductee on February 8 at a black-tie event at The Pierre Hotel in New York City. Leverte’s prolific career has included founding ERS – an in-house ad agency at ER Squibb – co-founding Ruvane-Leverte advertising, serving as chairman at Bozell Jacobs Medical Group, and operating as CEO of the Leverte Companies.

Read More »

Medical marketing escapes ad tax, for now

Although the passage of the 2017 tax bill was a victory for pharma and medical marketers, major challenges are ahead for those of us inside the Beltway for the foreseeable future.

Read More »

PALIO, GSW merge under GSW brand

The rebranding of INC Research/inVentiv Health to Syneos Health in the beginning of 2018 was just the first of more changes within the company. In the rebranded company’s Syneos Health Communications subsidiary, the healthcare communication agencies GSW and PALIO have been combined under the GSW brand name.

Read More »

Three new leaders at McCann Health

McCann Health expanded its executive team with three significant appointments. Marcus Sigurdsson was named to the new position of global chief digital officer. Linda Szyper was appointed to the new position of global chief operating officer. June Laffey was named to the new position of executive VP, chief creative officer, McCann Health New York.

Read More »

Publicis Health appoints new CEO and chief growth officer

Publicis Health promoted Alexandra von Plato to the role of CEO and Michael du Toit was named chief growth officer.

Read More »

W2O Group appoints new president

Jennifer Gottlieb was appointed president of W2O Group, a network of complementary analytics and insights-driven, digital marketing communications firms. In this newly created role, Gottlieb has responsibility for three operating companies – W2O wcg, W2O twist, and W2O pure. Gottlieb continues to report to founder and CEO Jim Weiss, who retains responsibility for overall firm strategy and operations globally as well as business development, innovation, and marketing.

Read More »

Page 4 of 10« First...23456...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom